You are here

FDA Grants Priority Review for Leukemia Drug Obinutuzumab

Approval decision expected in December (July 2)

The FDA has accepted a Biologics License Application (BLA) for obinutuzumab (GA101, Genentech) and has granted the drug priority review for the treatment of chronic lymphocytic leukemia (CLL), one of the most common forms of blood cancer.

The agency’s action date was set for December 20, 2013.

The FDA is evaluating data from the pivotal phase III CLL11 trial, in which obinutuzumab demonstrated a statistically significant 86% reduction in the risk of disease worsening or death (hazard ratio = 0.14; P

The most common grade-3 or -4 adverse events for obinutuzumab were infusion-related reactions (IRRs) and low cell counts of certain white blood cells (neutropenia), which did not result in an increased risk of infection. The incidence and severity of IRRs decreased after the first infusion of obinutuzumab, and no grade-3 or -4 IRRs have been reported beyond the first infusion.

Obinutuzumab is currently being investigated in a large clinical trial program that includes head-to-head phase III studies versus rituximab in indolent non-Hodgkin’s lymphoma (NHL) and in diffuse large B-cell lymphoma (DLBCL).

Source: Genentech; July 2, 2013.

Recent Headlines

Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
So far in January, the increases average 5%
Fast-acting insulin aspart may simplify mealtime dosing
Simple change in dosage and route may improve a century-old vaccine
Neurodevelopmental deficits detected in Colombian toddlers